Author

Satish Valluri

Observed names: S Valluri, S. Valluri, Satish C Valluri, Valluri, Satish

Observed institutions: University of Maryland, Baltimore, Bayer (United States), Pfizer (United States), Janssen (United States), Janssen Scientific Affairs (United States), The Ohio State University

ORCID: 0000-0001-9588-7238

Observed ORCID: 0000-0001-9588-7238

OpenAlex ID: A5043040581

A three-country comparison of psychotropic medication prevalence in youth

2008 · Julie M Zito, Daniel J Safer, et al. · Child and Adolescent Psychiatry and Mental Health · 203

PDF

The burden of non-radiographic axial spondyloarthritis

2014 · Annelies Boonen, Joachim Sieper, et al. · Seminars in Arthritis and Rheumatism · 136

Psychotherapeutic Medication Prevalence in Medicaid-Insured Preschoolers

2007 · Julie M. Zito, Daniel J. Safer, et al. · Journal of Child and Adolescent Psychopharmacology · 111

Impact of the 2004 Food and Drug Administration Pediatric Suicidality Warning on Antidepressant and Psychotherapy Treatment for New-Onset Depression

2010 · Satish Valluri, Julie M. Zito, et al. · Medical Care · 60

Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

2021 · Tom Martin, Saad Z. Usmani, et al. · Current Medical Research and Opinion · 48

PDF

Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma

2021 · Luciano J. Costa, Yi Lin, et al. · Clinical Lymphoma Myeloma & Leukemia · 44

Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma

2023 · Sundar Jagannath, Nedra Joseph, et al. · Oncology and Therapy · 32

PDF

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma

2021 · Thomas Martin, Amrita Krishnan, et al. · eJHaem · 31

PDF

Medical Costs Associated with Use of Systemic Therapy in Adults with Colorectal Cancer

2013 · Brian S. Seal, Sean D. Sullivan, et al. · Journal of Managed Care Pharmacy · 28

PDF

Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

2022 · Tom Martin, Saad Z. Usmani, et al. · Current Medical Research and Opinion · 27

Drug utilization and cost in a Medicaid population: A simulation study of community vs. mail order pharmacy

2007 · Satish Valluri, Enrique Seoane-Vazquez, et al. · BMC Health Services Research · 24

PDF

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

2021 · Katja Weisel, Thomas Martin, et al. · Clinical Drug Investigation · 23

PDF

Illustrating the impact of mild/moderate and severe haemophilia on health‐related quality of life: hypothesised conceptual models

2014 · Emuella Flood, Jennifer Pocoski, et al. · European Journal Of Haematology · 23

Impact of Metastatic Colorectal Cancer Stage and Number of Treatment Courses on Patient Health Care Costs and Utilization

2013 · Benjamin Chastek, Mahesh Kulakodlu, et al. · Postgraduate Medicine · 21

Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database

2024 · Binod Dhakal, Hermann Einsele, et al. · Blood Advances · 20

Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study

2022 · Adam D. Cohen, Parameswaran Hari, et al. · Clinical Lymphoma Myeloma & Leukemia · 18

Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

2022 · Katja Weisel, Amrita Krishnan, et al. · Clinical Lymphoma Myeloma & Leukemia · 17

Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan

2019 · Der-Yuan Chen, Ping-Ning Hsu, et al. · Journal of Medical Economics · 15

Real-World Treatment Patterns, Healthcare Resource Use and Disease Burden in Patients with Multiple Myeloma in Europe

2023 · Joaquín Martínez-Lopez, Abigail Bailey, et al. · Future Oncology · 13

Systemic Therapy for Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in Nationally Representative US Claims Database

2013 · Brian S. Seal, Sean D. Sullivan, et al. · BioDrugs · 12

The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies

2022 · Rebecca Crawford, Katharine S. Gries, et al. · Cancer Reports · 11

PDF

Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.

2021 · Luciano J. Costa, Yi Lin, et al. · Journal of Clinical Oncology · 10

Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma

2024 · Meletios Dimopoulos, Pieter Sonneveld, et al. · BMC Cancer · 9

P899: Real-world Assessment of Treatment Patterns and Outcomes in Patients With Lenalidomide-refractory Relapsed/refractory Multiple Myeloma From the Optum Database

2022 · B. Dhakal, H. Einsele, et al. · HemaSphere · 9

Total Car-T Cost of Care Beyond the Price of Car-T Cell Therapy in Patients with Multiple Myeloma

2021 · Sundar Jagannath, Nedra Joseph, et al. · Blood · 9

Works count: 76

Citation count: 1,012

H-index: 17

I10-index: 22